AR026255A1 - Combinaciones antivirales. - Google Patents

Combinaciones antivirales.

Info

Publication number
AR026255A1
AR026255A1 ARP000105645A ARP000105645A AR026255A1 AR 026255 A1 AR026255 A1 AR 026255A1 AR P000105645 A ARP000105645 A AR P000105645A AR P000105645 A ARP000105645 A AR P000105645A AR 026255 A1 AR026255 A1 AR 026255A1
Authority
AR
Argentina
Prior art keywords
hbv
combinations
refers
nucleoside
antiviral combinations
Prior art date
Application number
ARP000105645A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR026255A1 publication Critical patent/AR026255A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP000105645A 1999-10-29 2000-10-26 Combinaciones antivirales. AR026255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/429,863 US6432966B2 (en) 1999-10-29 1999-10-29 Antiviral combinations

Publications (1)

Publication Number Publication Date
AR026255A1 true AR026255A1 (es) 2003-02-05

Family

ID=23705033

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105645A AR026255A1 (es) 1999-10-29 2000-10-26 Combinaciones antivirales.

Country Status (10)

Country Link
US (1) US6432966B2 (cg-RX-API-DMAC7.html)
EP (1) EP1225904B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003512421A (cg-RX-API-DMAC7.html)
AR (1) AR026255A1 (cg-RX-API-DMAC7.html)
AT (1) ATE273012T1 (cg-RX-API-DMAC7.html)
AU (1) AU1042701A (cg-RX-API-DMAC7.html)
DE (1) DE60012961T2 (cg-RX-API-DMAC7.html)
ES (1) ES2225245T3 (cg-RX-API-DMAC7.html)
TW (1) TWI282735B (cg-RX-API-DMAC7.html)
WO (1) WO2001030329A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229775A1 (en) * 2000-02-29 2001-09-12 Bristol-Myers Squibb Company Low dose entecavir formulation and use
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US8168568B1 (en) * 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
CN102552210B (zh) * 2012-01-10 2013-12-11 四川海思科制药有限公司 一种恩替卡韦胶囊组合物及其制备方法
KR20170132327A (ko) * 2015-04-07 2017-12-01 스프링 뱅크 파마슈티칼스, 인크. Hbv 감염의 치료를 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800452D0 (sv) * 1998-02-13 1998-02-13 Medivir Ab Antivirals
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
ATE131730T1 (de) 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
EP0988042B1 (en) * 1997-04-15 2008-01-09 Advanced Viral Research Corp. Combination of product r and an antiviral agent in the therapy of hiv infections
AU738472B2 (en) * 1997-09-25 2001-09-20 Cornell Research Foundation Inc. Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection

Also Published As

Publication number Publication date
DE60012961T2 (de) 2005-08-18
DE60012961D1 (de) 2004-09-16
EP1225904A2 (en) 2002-07-31
ATE273012T1 (de) 2004-08-15
ES2225245T3 (es) 2005-03-16
US20020002180A1 (en) 2002-01-03
TWI282735B (en) 2007-06-21
EP1225904B1 (en) 2004-08-11
JP2003512421A (ja) 2003-04-02
US6432966B2 (en) 2002-08-13
WO2001030329A2 (en) 2001-05-03
AU1042701A (en) 2001-05-08
WO2001030329A3 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
Torresi et al. Antiviral chemotherapy for the treatment of hepatitis B virus infections
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
MY109796A (en) 1,3-oxathiolane nucleoside analogues.
CY1108355T1 (el) Συνθεσεις και μεθοδοι για συνδυασμενη αντι-ιικη θεραπεια
MXPA02011635A (es) Metodos y composiciones para el tratamiento del virus de la hepatitis c.
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
GEP20022647B (en) Synergistic Combinations
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
PA8588501A1 (es) Derivados antivirales de nucleósidos
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
ES2138969T3 (es) Combinacion de nucleosidos antivirales.
NO20034878L (no) Antivirale forbindelser
AR023661A1 (es) Combinaciones antivirales
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
WO2001030329A3 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
AR040242A1 (es) Composiciones farmaceuticas
WO2004043402A3 (en) Modified nucleosides as antiviral agents
AR043332A1 (es) Composiciones y metodos para terapia antiviral
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral
RU2005138167A (ru) Противовирусное средство (варианты) и способ лечения на его основе
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
WO2000016754A3 (en) Antiviral combinations comprising lamivudine and lobucavir
AR019532A1 (es) COMPOSICIoN FARMACÉUTICA DEL COMPUESTO 1,5-DIDEOXI-1,5-IMIN-D-GLUCITOL N-SUSTITUIDO

Legal Events

Date Code Title Description
FA Abandonment or withdrawal